Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood sampling for dosage: 4ml blood sample to measure acid sphingomyelinase enzyme activity and LysoSM, if required.

Study summary

The goal of this clinical trial is to optimise and facilitate screening for Acid SphingoMyelinase Deficiency (ASMD) disease, by evaluating acid sphingomyelinase activity and, where appropriate, LysoSM levels in a cohort of 200 participants with diffuse interstitial lund disease (ILD) at risk of developing ASMD disease.

ILD is common in the general population, so in order to limit the number of differential diagnoses, the population to be studied will be restricted to participants aged between 15 years and 3 months and 60 years, with ILD plus ground-glass opacities on chest CT scan certified by a pulmonologist/radiologist or internist, AND splenomegaly or splenectomy, and/or thrombocytopenia, and/or low HDL cholesterol, and/or parental consanguinity which increase the sensitivity of ASMD screening.

In this clinical trail, two procedures are added, participants will be asked for :

* a blood sample to measure the acid sphingomyelinase enzyme activity and LysoSM, if required.
* a follow-up visit at 6 months

Eligibility

Primary outcome measure(s)

• ASMD Screening Outcomes in Adults with Diffuse Interstitial Lung Disease — 60 months
  Diagnostic performance of a sequential combined dried blood spot screening strategy for ASMD, assessed by the proportion of patients with abnormal acid sphingomyelinase enzymatic activity and/or elevated lysoSM concentrations, and by the number of confirmed ASMD diagnoses identified among 200 patients with interstitial lung disease at risk for ASMD.

Trial sites (1)

More Wladimir MAUHIN, Dr trials in France

Other trials for the same condition